BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTC PINK: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product.

The study design was similar to that of a previously successful 28-day challenge study but was extended through 42 days to replicate real-world conditions of the broiler production industry. The results of the study in which the ZIVO treatment groups and a placebo control were blinded to the independent study contractor confirm previously reported positive effects of ZIVO’s non-antibiotic alternative for maintaining broiler health against coccidiosis. Notably, the study also showed that the performance of ZIVO’s product candidate was comparable to that of a market leading anticoccidial product.

“We are delighted to report results that validate our prior 28-day study in broiler chickens, and we are particularly excited to report that our product performance compared favorably to a market leading product containing an antibiotic and an anti-coccidial chemical. The outcomes of our studies demonstrate that our coccidiosis treatment is efficacious in real-world conditions, yet without the undesirable characteristics associated with antibiotics and chemicals,” said John Payne, Chairman and Chief Executive Officer of ZIVO Bioscience.

“Not only do our results show our candidate’s effectiveness in counteracting or eliminating adverse effects of coccidiosis on gastrointestinal health of broiler chickens, we are confident that similar results will be obtained in the commercial broiler production environment at cost parity with conventional antibiotic and antimicrobial interventions. As a result, our product exhibits promising potential to revolutionize poultry health management. Our next step is to use these results to engage a global animal health partner to complete licensing through the USDA and commercialize the product,” Mr. Payne added.

About Coccidiosis

Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billionⁱ. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that industry and consumers alike wish to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.

About ZIVO Bioscience

ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.

Forward Looking Statements

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected time frame for results of future studies. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

ⁱ Blake, D.P., Knox, J., Dehaeck, B. et al. Re-calculating the cost of coccidiosis in chickens. Vet Res 51, 115 (2020). https://doi.org/10.1186/s13567-020-00837-2

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123148730/en/